Delayed-Release Micronutrient Formulation for Colon SCFA Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations fail to effectively increase short-chain fatty acid concentrations, microbiome diversity, and butyrate synthesis in the lower intestinal tract, while also failing to improve gut barrier function and stimulate immune responses, which are associated with various health issues such as inflammatory bowel diseases and metabolic disorders.
Innovation Solution
Administering a delayed release formulation containing micronutrients like riboflavin, vitamins, and omega-3 fatty acids to the large intestine, which increases short-chain fatty acid production, enhances microbiome diversity, promotes butyrate synthesis, and improves gut barrier function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional formulations are used, then the formulations are simple and easy to manufacture, but they fail to effectively increase short-chain fatty acid concentrations, microbiome diversity, and butyrate synthesis in the lower intestinal tract
Solution Approach 1:
The formulation is segmented into multiple functional components: probiotic bacteria (Bifidobacterium, Lactobacillus, Faecalibacterium), prebiotic fibers (inulin, fructooligosaccharides, resistant starch), and micronutrients (riboflavin, vitamins A, C, D, E, K, B1, B6, B12, folic acid, biotin). Each component targets specific aspects of gut health, and their combination creates synergistic effects that conventional single-component formulations cannot achieve.
Solution Approach 2:
The invention uses a composite formulation combining multiple biological active substances working together. The probiotics provide direct microbial benefits, prebiotics serve as food for beneficial bacteria, and micronutrients act as cofactors for metabolic processes. This composite approach creates a multi-functional system that simultaneously increases SCFA production, enhances microbiome diversity, and promotes butyrate synthesis.
2Reliability
If conventional formulations are used, then the formulations have simple composition, but they fail to improve gut barrier function and stimulate immune responses
Solution Approach 1:
The formulation is designed with multi-functionality, where each component contributes to multiple health outcomes. For example, short-chain fatty acids produced by the probiotics serve both as energy sources for colonocytes and as signaling molecules that enhance barrier function and modulate immune responses. The prebiotic fibers simultaneously feed beneficial bacteria and provide structural support for the gut lining. This multi-functional design allows a single formulation to address multiple aspects of gut health simultaneously.
Solution Approach 2:
The formulation uses intermediaries such as short-chain fatty acids and microbial metabolites that mediate between the probiotic bacteria and the host gut lining. These intermediaries act as signaling molecules that trigger barrier reinforcement and immune modulation, bridging the gap between microbial presence and host physiological response.
3Productivity
If micronutrients are administered to increase SCFA and microbiome diversity, then health benefits are achieved, but gas production may increase
Solution Approach 1:
The formulation optimizes parameters such as the ratios of different probiotic strains, the types and amounts of prebiotic fibers, and the specific micronutrient combinations to enhance beneficial microbial activity while minimizing gas-producing fermentation. By carefully controlling these parameters, the formulation promotes SCFA production pathways that are less gas-intensive while maintaining microbiome diversity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively increases short-chain fatty acid concentrations, microbiome diversity, and butyrate synthesis, reduces gas production, and enhances gut barrier function, thereby treating or preventing disorders like inflammatory bowel disease and metabolic disorders.
Implementation Method 1
Dietary fibers, but also proteins and peptides, which escape digestion by host enzymes in the upper gut, are metabolized by the microbiota in the cecum and colon. The major products from the microbial fermentative activity in the gut are SCFAs—in particular, acetate, propionate, and butyrate.
Implementation Method 2
The formulations of the present invention can be used for increasing the butyrate synthesis pathway in the lower intestinal tract.
Data Source
AI summary
Various benefits to intestinal health are made by delivery of an active agent to the colon of an animal, including a human. Active ingredients include of riboflavin, vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, β-carotene, vitamin B1, niacin, vitamin B5, vitamin B6, biotin, vitamin B12, omega-3 fatty acids and combinations thereof. Benefits include increased concentration of at least one short-chain fatty acid its salt thereof in the intestine, increased microbiome diversity in the intestine, increased beneficial bacteria in the intestine, increased the butyrate synthesis pathway in the intestine, improved barrier function of the intestine, reduced redox potential of the gut, reduced amount of gas produced in the intestine; and stimulation of intestinal immune responses.